PMID- 27898363
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20170313
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 45
DP  - 2017 Feb
TI  - The adverse event profile of brivaracetam: A meta-analysis of randomized 
      controlled trials.
PG  - 7-16
LID - S1059-1311(16)30214-X [pii]
LID - 10.1016/j.seizure.2016.11.008 [doi]
AB  - PURPOSE: To comprehensively evaluate the adverse events (AEs) significantly 
      associated with brivaracetam (BRV) treatment in a large selection of randomized 
      control trials. METHODS: We conducted an online database search using Pubmed, 
      Embase, Cochrane Online Library, and Clinicaltrial.gov for all available 
      randomized control trials (RCTs) that investigated the therapeutic effects of 
      brivaracetam. Serious AEs (SAEs), withdrawal, and treatment-emergent adverse 
      effects were then assessed for their association with brivaracetam. Finally, a 
      meta-analysis was performed using Review Manager 5.3 software. RESULTS: Eight 
      RCTs with a total of 2505 patients were included in our study, 1178 of which were 
      randomized with respect to brivaracetam (BRV). Serious AEs, overall withdrawal, 
      AE-related withdrawal and psychiatric adverse events (PAEs) were not 
      significantly associated with BRV treatment. BRV was also not significantly 
      associated with a heightened risk of AE-related withdrawal and PAEs with 
      increasing doses. Of the 17 AEs included in our meta-analysis, three AEs 
      (dizziness, fatigue, and back pain) were found to be significantly associated 
      with BRV treatment. But we did not find that the risk of them was obviously 
      increasing with the increasing doses. CONCLUSION: This meta-analysis showed that 
      BRV treatment was reasonably tolerated by patients and rarely caused serious AEs. 
      Further clinical studies will be needed to more concretely determine the safety 
      and tolerability profile of BRV.
CI  - Copyright (c) 2016 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Zhu, Li-Na
AU  - Zhu LN
AD  - Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue 
      Lane 37#, Chengdu 610041, Sichuan, China. Electronic address: 
      Angelinazhuzhu@163.com.
FAU - Chen, Deng
AU  - Chen D
AD  - Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue 
      Lane 37#, Chengdu 610041, Sichuan, China. Electronic address: jerry.k.d@163.com.
FAU - Chen, Tao
AU  - Chen T
AD  - Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue 
      Lane 37#, Chengdu 610041, Sichuan, China. Electronic address: 417358610@qq.com.
FAU - Xu, Da
AU  - Xu D
AD  - Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue 
      Lane 37#, Chengdu 610041, Sichuan, China. Electronic address: 498688793@qq.com.
FAU - Chen, Si-Han
AU  - Chen SH
AD  - Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue 
      Lane 37#, Chengdu 610041, Sichuan, China. Electronic address: 
      13608223283@163.com.
FAU - Liu, Ling
AU  - Liu L
AD  - Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue 
      Lane 37#, Chengdu 610041, Sichuan, China. Electronic address: zjllxx1968@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20161114
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 0 (Pyrrolidinones)
RN  - U863JGG2IA (brivaracetam)
SB  - IM
MH  - Anticonvulsants/*adverse effects
MH  - Databases, Bibliographic/statistics & numerical data
MH  - Epilepsy/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Disorders/*chemically induced
MH  - Pyrrolidinones/*adverse effects
MH  - *Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Adverse effects
OT  - Antiepileptic drug
OT  - Brivaracetam
EDAT- 2016/11/30 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/11/30 06:00
PHST- 2016/07/21 00:00 [received]
PHST- 2016/09/26 00:00 [revised]
PHST- 2016/11/08 00:00 [accepted]
PHST- 2016/11/30 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
PHST- 2016/11/30 06:00 [entrez]
AID - S1059-1311(16)30214-X [pii]
AID - 10.1016/j.seizure.2016.11.008 [doi]
PST - ppublish
SO  - Seizure. 2017 Feb;45:7-16. doi: 10.1016/j.seizure.2016.11.008. Epub 2016 Nov 14.